Kuros statement on media inquiry concerning former Board member

Core Viewpoint - Kuros Biosciences is currently investigating the resignation of former Board member Albert Arp, who allegedly resigned due to sharing price-sensitive information with a third party, but the company asserts this matter does not affect its strategic direction or financial performance [1]. Company Overview - Kuros Biosciences is focused on innovative biologic technologies and is listed on the SIX Swiss Exchange, with operations in the United States, Switzerland, and the Netherlands [5]. - The company's flagship product, MagnetOs, is an advanced bone graft used globally across four continents [5]. Product Information - MagnetOs has demonstrated a fusion rate of 79% in a Level I clinical study, nearly double that of autograft at 47% for posterolateral fusions [3]. - Among active smokers, the fusion rate difference was even more pronounced, although specific data for this subgroup was not statistically analyzed [3][7]. - MagnetOs utilizes NeedleGrip technology to stimulate bone growth without added cells or growth factors, and it is FDA cleared for use throughout the spine [3]. Regulatory and Usage Notes - MagnetOs is not cleared as an osteoinductive bone graft and must be used with an FDA-cleared intervertebral body fusion device [8].